Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $35.46 USD
Change Today -1.61 / -4.34%
Volume 152.3K
ZFGN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

zafgen inc (ZFGN) Snapshot

Open
$36.60
Previous Close
$37.07
Day High
$36.82
Day Low
$35.06
52 Week High
03/20/15 - $55.36
52 Week Low
10/15/14 - $16.01
Market Cap
952.3M
Average Volume 10 Days
185.4K
EPS TTM
--
Shares Outstanding
26.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZAFGEN INC (ZFGN)

Related News

No related news articles were found.

zafgen inc (ZFGN) Related Businessweek News

No Related Businessweek News Found

zafgen inc (ZFGN) Details

Zafgen, Inc., a biopharmaceutical company, focuses on the development of therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate includes Beloranib, an injection, which is in Phase III clinical trials for the treatment of obesity and hyperphagia in Prader-Willi Syndrome patients; that has completed Phase II clinical trials for the treatment of hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which is in Phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a methionine aminopeptidase 2 inhibitor, which is in preclinical studies to reduce the severity of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and abdominal obesity. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.

22 Employees
Last Reported Date: 03/25/15
Founded in 2005

zafgen inc (ZFGN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $425.0K
President
Total Annual Compensation: $195.4K
Chief Financial Officer
Total Annual Compensation: $297.9K
Chief Medical Officer
Total Annual Compensation: $407.0K
Chief Commercial Officer
Total Annual Compensation: $328.8K
Compensation as of Fiscal Year 2014.

zafgen inc (ZFGN) Key Developments

Zafgen, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Zafgen, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported a net loss attributable to common stockholders of $10,931,000, or $0.48 per basic and diluted share compared to a $3,899,000 or $5.35 per basic and diluted share, for the three months ended December 31, 2013. Loss from operations was $10,664,000 compared with $3,761,000 for the same period a year ago. For the year, the company reported loss from operations of $35,532,000 against $13,780,000 a year ago. Net loss attributable to common stockholders was $36,570,000 or $3.00 per basic and diluted share against $14,240,000 or $19.53 per basic and diluted share a year ago.

Zafgen, Inc., Q4 2014 Earnings Call, Mar 19, 2015

Zafgen, Inc., Q4 2014 Earnings Call, Mar 19, 2015

Zafgen, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 02:00 PM

Zafgen, Inc. Presents at 12th Annual BIO Asia International Conference, Mar-24-2015 02:00 PM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZFGN:US $35.46 USD -1.61

ZFGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZFGN.
View Industry Companies
 

Industry Analysis

ZFGN

Industry Average

Valuation ZFGN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZAFGEN INC, please visit www.zafgen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.